TONG REN TANG (01666) released its mid-term performance report, with a net profit attributable to the parent company of 249 million yuan, a year-on-year decrease of 26.43%.

TONG REN TANG (01666) announced its interim results for the six months ending June 30, 2026. The group achieved revenue of 3.024 billion yuan, a year-on-year decrease of 19.1%; net profit attributable to the parent company was 249 million yuan, a year-on-year decrease of 26.43%; earnings per share were 0.19 yuan. During the reporting period, the group adhered to a general business guideline of seeking progress while maintaining stability, focusing on the work principle of "changing concepts, emphasizing coordination, improving quality and efficiency, strengthening execution, enhancing management, and building confidence." The group centered its efforts on its main business in traditional Chinese medicine, continuously advancing the reform of its marketing system and optimizing production operations. Due to changes in the industry environment, adjustments in market demand, and the group's proactive optimization of channel operations strategies, the group's performance declined during this period. In response to market changes, the group continued to promote the cultivation of core products, optimization of product structure, and enhancement of operational efficiency. Various strategic measures were steadily implemented, maintaining a stable foundation for core business, thereby laying a groundwork for long-term sustainable development.